Issue 13, 2022

The indole nucleus as a selective COX-2 inhibitor and anti-inflammatory agent (2011–2022)

Abstract

Here we have outlined the recent (2011–2022) developments in the synthesis of modified indomethacin-based analogues for the selective inhibition of COX-2 and then highlighted the synthesis of indoles as inhibitors of other inflammatory mediators such as nitric oxide (NO) radicals, lipoxygenase (LOX) enzymes, reactive oxygen species (ROS) and interleukin (IL).

Graphical abstract: The indole nucleus as a selective COX-2 inhibitor and anti-inflammatory agent (2011–2022)

Article information

Article type
Review Article
Submitted
01 Apr. 2022
Accepted
12 Maijs 2022
First published
16 Maijs 2022

Org. Chem. Front., 2022,9, 3624-3639

The indole nucleus as a selective COX-2 inhibitor and anti-inflammatory agent (2011–2022)

Nisha, S. Singh, N. Sharma and R. Chandra, Org. Chem. Front., 2022, 9, 3624 DOI: 10.1039/D2QO00534D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements